BADDIE
Health
powered by FELLA HEALTH
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become widely prescribed for type 2 diabetes and weight management across the United States. As more patients undergo elective surgery while taking these medications, understanding how long to hold GLP-1 prior to surgery has become a critical safety consideration. Current guidance from the American Society of Anesthesiologists emphasizes a risk-based approach rather than universal holding periods. This article reviews evidence-based recommendations for managing GLP-1 medications before surgical procedures, helping patients and clinicians make informed perioperative decisions.
Summary: Most patients can continue GLP-1 medications before elective surgery, but high-risk patients with active GI symptoms or recent dose changes may need to hold daily agents on surgery day or skip weekly doses scheduled for the surgery week.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become widely prescribed medications for type 2 diabetes and weight management in the United States. These agents—including semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)—work by mimicking the incretin hormone GLP-1, which slows gastric emptying, enhances insulin secretion, and reduces appetite.
The primary consideration with GLP-1 therapy before surgery relates to their effect on gastric motility. By delaying gastric emptying, these medications may affect gastric contents despite standard preoperative fasting periods. This has raised questions about aspiration risk during anesthesia induction and intubation.
Importantly, current guidance from the American Society of Anesthesiologists (ASA) and multiple specialty societies (October 2024) indicates that most patients can continue GLP-1 RAs before elective procedures. This represents an evolution from earlier recommendations that suggested universal holding periods.
The current risk-based approach focuses on identifying high-risk patients who may benefit from additional precautions or medication adjustment. High-risk factors include:
Active gastrointestinal symptoms (nausea, vomiting, early satiety)
Recent dose escalation or initiation
Known gastroparesis or other motility disorders
History of severe reflux disease
Healthcare providers must balance the metabolic benefits of continued GLP-1 therapy against potential perioperative risks, making individualized decisions based on the specific agent, patient symptoms, and type of surgical procedure planned. Patients should not discontinue these medications without explicit guidance from their healthcare team.
Current guidance from the ASA-led multi-society consensus (2024) recommends a risk-stratified approach to managing GLP-1 medications before surgery, rather than universal holding periods.
For most patients:
Continue GLP-1 medications as prescribed
Consider a 24-hour clear liquid diet before the procedure
Inform the anesthesia team about GLP-1 use
Follow standard preoperative fasting guidelines
For high-risk patients (those with active GI symptoms, recent dose escalation, or known gastroparesis):
Options may include:
A 24-hour clear liquid diet before the procedure
Point-of-care gastric ultrasound assessment
Full-stomach precautions during anesthesia
Consideration of holding the medication:
These recommendations apply to elective surgical procedures. For urgent or emergency surgery, the anesthesia team must be informed of recent GLP-1 use so appropriate precautions can be taken, including modified rapid sequence induction techniques when indicated.
Patients should discuss their specific situation with both their prescribing physician and surgical team. The goal is to maintain glycemic control and metabolic benefits while ensuring perioperative safety. For patients with diabetes, coordination with the diabetes care team is essential to establish appropriate glycemic management during the perioperative period.
GLP-1 receptor agonists can affect gastrointestinal motility by activating GLP-1 receptors in the gastric fundus and antrum, potentially delaying gastric emptying through both central and peripheral pathways. This pharmacologic effect, while therapeutically beneficial for glycemic control and weight loss, has raised questions about perioperative management.
Studies using gastric emptying scintigraphy have demonstrated that GLP-1 RAs can delay gastric emptying, particularly for solid foods, though the magnitude varies by agent, dose, and duration of therapy. Importantly, this effect often attenuates with chronic use (tachyphylaxis), meaning long-term users may have less pronounced gastric emptying delays than those recently starting therapy.
Case reports have documented instances where solid food was retained in the stomach of patients taking GLP-1 medications despite adherence to standard fasting protocols. However, it's important to note that clinically significant aspiration events appear to be rare, and the evidence base consists primarily of case reports and observational studies rather than large controlled trials.
Pulmonary aspiration occurs when gastric contents enter the tracheobronchial tree, typically during the vulnerable period of anesthesia induction or emergence when protective airway reflexes are diminished. The severity depends on the volume and pH of aspirated material.
The risk assessment should focus on patient-specific factors, including:
Presence of GI symptoms (nausea, vomiting, early satiety)
Timing of the most recent dose and dose escalation status
Duration of therapy (newer users may have more pronounced effects)
Differential effects on solids versus liquids (liquids typically empty more rapidly)
This understanding supports the current approach of using a 24-hour clear liquid diet before procedures for high-risk patients, as liquids are less affected by the gastric-slowing effects of GLP-1 medications. Point-of-care gastric ultrasound can also help assess residual gastric volume in uncertain cases.
Transparent communication about GLP-1 medication use is essential for patient safety in the perioperative period. Patients should proactively disclose their use of these medications during preoperative consultations, as surgeons and anesthesiologists need this information to make informed decisions about perioperative management.
Key information to provide includes:
The specific name and dose of your GLP-1 medication (brand and generic names)
How long you have been taking the medication
Your dosing schedule (daily or weekly)
The date of your most recent dose
Whether you're in a dose escalation phase
Any gastrointestinal symptoms you're experiencing, particularly nausea, vomiting, or feeling of delayed stomach emptying
Any history of gastroparesis or severe reflux disease
Many patients do not realize that weight-loss medications like Wegovy and diabetes medications like Ozempic contain the same active ingredient (semaglutide) and have similar effects on gastric emptying. It is crucial to mention all GLP-1 medications regardless of the indication for which they were prescribed.
If you are taking a GLP-1 medication and have an upcoming surgical procedure, contact your surgical team as soon as possible—ideally at the time of scheduling. This allows adequate time to develop an appropriate perioperative plan. For patients with diabetes, coordination with the prescribing endocrinologist or primary care physician is important to ensure proper glycemic management throughout the perioperative period.
Importantly, do not stop your GLP-1 medication without specific instructions from your healthcare team. In most cases, continuing your medication with appropriate precautions (such as a clear liquid diet for 24 hours before surgery) may be recommended rather than discontinuation.
The decision about when to restart GLP-1 medications after surgery requires individualized assessment based on the type of procedure performed, postoperative course, and return of normal gastrointestinal function. There is currently no universal consensus on optimal timing for resumption, and recommendations should be made collaboratively between the surgical team and the prescribing physician.
General considerations for resuming GLP-1 therapy include:
For minor outpatient procedures with rapid recovery, GLP-1 medications may potentially be resumed once the patient has fully recovered from anesthesia, is tolerating oral intake without nausea or vomiting, and has been cleared by the surgical team. This might be as soon as 24 to 48 hours postoperatively for straightforward cases, though timing should be individualized.
For major abdominal or gastrointestinal surgery, a more conservative approach is warranted. Patients should demonstrate return of bowel function (passing flatus, having bowel movements), tolerance of regular diet without significant nausea, and absence of postoperative complications before restarting GLP-1 therapy. This may require waiting one to two weeks depending on the specific procedure and individual recovery.
Patients who experience postoperative nausea, vomiting, or ileus should delay resumption until these issues have completely resolved, as GLP-1 medications can exacerbate gastrointestinal symptoms. Similarly, any anastomotic complications or concerns about gastrointestinal healing should prompt postponement of GLP-1 therapy.
For patients with diabetes, alternative glycemic management strategies will be necessary if GLP-1 therapy is held. This may include temporary use of basal insulin, short-acting insulin, or other oral agents as directed by the diabetes care team, following American Diabetes Association perioperative guidelines. Blood glucose monitoring should be intensified during this transition period.
When restarting GLP-1 medications after a prolonged interruption, some clinicians recommend re-initiating at a lower dose and gradually titrating to minimize gastrointestinal side effects, particularly if the patient experienced significant GI symptoms when first starting the medication. Patients should maintain close communication with their prescribing physician and surgical team throughout the perioperative period.
Most patients can continue GLP-1 medications before elective surgery. However, high-risk patients with active gastrointestinal symptoms, recent dose changes, or known gastroparesis may need to hold their medication—daily agents on surgery day or weekly agents for the week of surgery—based on individualized assessment by their healthcare team.
GLP-1 receptor agonists delay gastric emptying, which may result in retained stomach contents despite standard fasting protocols. This raises potential aspiration risk during anesthesia induction, though clinically significant events appear rare and current guidance emphasizes risk-based rather than universal precautions.
Timing depends on the procedure type and recovery. After minor outpatient procedures, GLP-1 medications may resume within 24-48 hours once you tolerate oral intake. After major abdominal surgery, wait until bowel function returns and you tolerate regular diet without nausea, typically one to two weeks, with guidance from your surgical and prescribing teams.
All medical content on this blog is created using reputable, evidence-based sources and is regularly reviewed for accuracy and relevance. While we strive to keep our content current with the latest research and clinical guidelines, it is intended for general informational purposes only.
This content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider with any medical questions or concerns. Use of this information is at your own risk, and we are not liable for any outcomes resulting from its use.
